Home
>
National Drug Code (NDC)
>
amlodipine besylate and benazepril hydrochloride
amlodipine besylate and benazepril hydrochloride - 0615-1397-39 - (amlodipine besylate and benazepril hydrochloride)
Drug Information of amlodipine besylate and benazepril hydrochloride
| Product NDC: | 0615-1397 |
| Proprietary Name: | amlodipine besylate and benazepril hydrochloride |
| Non Proprietary Name: | amlodipine besylate and benazepril hydrochloride |
| Active Ingredient(s): | 5; 10 mg/1; mg/1 & nbsp; amlodipine besylate and benazepril hydrochloride |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of amlodipine besylate and benazepril hydrochloride
| Product NDC: | 0615-1397 |
| Labeler Name: | NCS HealthCare of KY, Inc dba Vangard Labs |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA020364 |
| Marketing Category: | NDA |
| Start Marketing Date: | 19950303 |
Package Information of amlodipine besylate and benazepril hydrochloride
| Package NDC: | 0615-1397-39 |
| Package Description: | 30 CAPSULE in 1 BLISTER PACK (0615-1397-39) |
NDC Information of amlodipine besylate and benazepril hydrochloride
| NDC Code | 0615-1397-39 |
| Proprietary Name | amlodipine besylate and benazepril hydrochloride |
| Package Description | 30 CAPSULE in 1 BLISTER PACK (0615-1397-39) |
| Product NDC | 0615-1397 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | amlodipine besylate and benazepril hydrochloride |
| Dosage Form Name | CAPSULE |
| Route Name | ORAL |
| Start Marketing Date | 19950303 |
| Marketing Category Name | NDA |
| Labeler Name | NCS HealthCare of KY, Inc dba Vangard Labs |
| Substance Name | AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE |
| Strength Number | 5; 10 |
| Strength Unit | mg/1; mg/1 |
| Pharmaceutical Classes | Calcium Channel Antagonists [MoA],Dihydropyridine Calcium Channel Blocker [EPC],Dihydropyridines [Chemical/Ingredient],Angiontensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA],Decreased Blood Pressure [PE] |
